Untitled

Abstract

Morinda citrifolia L. (Rubeaceae) is a medicinal plant commonly called as Noni. Traditionally the entire plant is used for the treatment of cancer, inflammation, hypertension, diabetes, bacterial infections, and arthritis. The present study aims to explore the antineoplastic activity of Noni Juice (NJ) and Divine Noni Gold (DNG) concentrate on Ehrlich ascites carcinoma (EAC) bearing mice. Antineoplastic activity of NJ and DNG was evaluated in EAC bearing mice by administrating 0.35 ml/mouse p.o. respectively once daily for 14 days, before half an hour of NJ and DNG administration animal received single dose of cisplatin (CP) at the dose of 5.0 mg/kg b.w. i.p. on day 1 in respective cluster. Antitumor activity of NJ and DNG were measured by evaluating Mean Survival Time (MST), percentage Increase in Life Span (%ILS), body weight, tumor volume and viable cell count, additionally biochemical markers as well as hematological parameters were also evaluated. In the result, observed NJ and DNG respectively showed significant decrease tumor volume, viable cell count, body weight and raised MST and %ILS. Hematological parameters and serum biochemical markers were reverted and maintained closed to normal level in CP challenged mice. Results indicates that NJ and DNG possesses antineoplastic activity, this impact may be for the sake of their antioxidant and anti-angiogenic properties. In conclusion, NJ and DNG may be beneficial supplements in CP chemotherapy for enhancing the antitumor efficacy and decreasing the toxicity of CP.

Protective and Therapeutic Efficacy of Hesperidin versus Cisplatin against Ehrlich Ascites Carcinoma-Induced Renal Damage in Mice

“…Additionally, the impairment of renal functions might be due to the direct oxidative renal damaging effect of Cis on the tubular and glomerular structures via the excessive production of free radicals and the depletion of the renal antioxidant defense system [ 17 ], as evidenced in the current study by the observed increase in the renal MDA level and reductions in the GSH content and CAT activity in EAC-bearing mice treated with Cis. These results agreed fully with previous findings of Ali et al [ 49 ] and Longchar and Prasad [ 34 ]. In support of these results, the histopathological and immunohistochemical investigations ascertained the biochemical findings, where some vascular, degenerative, and necrotic changes with only a few neoplastic cells were observed in the renal tissue of EAC-bearing mice treated with Cis, along with weak Ki-67 and strong caspase-3 expressions of neoplastic cells infiltrating the renal capsule.…”

“…In support of these results, the histopathological and immunohistochemical investigations ascertained the biochemical findings, where some vascular, degenerative, and necrotic changes with only a few neoplastic cells were observed in the renal tissue of EAC-bearing mice treated with Cis, along with weak Ki-67 and strong caspase-3 expressions of neoplastic cells infiltrating the renal capsule. Similar findings were also observed by Ali et al [ 49 ], Hashem et al [ 17 ], and Longchar and Prasad [ 34 ], indicating the antitumor potency of Cis and its renal damaging adverse side effect.…”

“…Cis-treated (EAC then Cis) group: Mice were orally administered distilled water, day by day, for two weeks before EAC inoculation, and 3 days after EAC inoculation; mice were treated with a single i.p dose of Cis (5 mg/kg) [ 49 ].…”